• By ICR Secretariat
  • Posted Thursday, April 28, 2022

How a surprise finding made an Alnylam study one of biotech’s most ‘polarizing’ trials

https://www.biopharmadive.com/news/alnylam-ttr-cardiomyopathy-apollo-bridge-bio-trial/622480/

The outcome, no longer seen as a sure bet, could influence how future drugs for a deadly heart disease are developed.